I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 1.55% to $508.34 on Friday, underperforming the broader market as the S&P 500 rose slightly while the Dow dipped. The stock closed 9.27% below its 52-week high of $560.25 reached in September. Compared to competitors like AbbVie and Krystal Biotech, Vertex's performance was mixed amid a generally volatile trading session.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) shed 1.55% to $508.34 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.17% to 7,650.50 and the Dow Jones Industrial Average falling 0.18% to 51,682.64.
Vertex Pharmaceuticals Inc. closed 9.27% below its 52-week high of $560.25, which the company reached on September 3rd.
The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc. (ABBV) fell 0.02% to $263.96, Krystal Biotech Inc. (KRYS) fell 0.61% to $336.67, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 5.32% to $16.03.
Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-18-26 1636ET